Abstract:Congenital disorders of glycosylation with novel phenotypes and disruptive N‐glycan profiling caused by compound heterozygous MAN2B2 variants (NM_015274.1, c.384G>T; c.926T>A). Background Congenital disorders of glycosylation (CDG) are a type of inborn error of metabolism (IEM) resulting from defects in glycan synthesis or failed attachment of glycans to proteins or lipids. One rare type of CDG is caused by homozygous or compound heterozygous loss‐of‐function variants in mannosidase alpha class 2B member 2 (MAN2B2). To date, only two cases of MAN2B2‐CDG have been reported worldwide. Methods Trio whole‐exome sequencing (Trio‐WES) was conducted to screen for candidate variants. N‐glycan profiles were measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS). MAN2B2 expression was evaluated by western blotting. MX dynamin like GTPase 1 (MX1) function was estimated via Thogoto virus (THOV) minireplicon assay. Results Trio‐WES identified compound heterozygous MAN2B2 (hg19, NM_015274.1) variants (c.384G>T; c.926T>A) in a CDG patient. This patient exhibited metabolic abnormalities, symptoms of digestive tract dysfunction, infection, dehydration, and seizures. Novel immune dysregulation characterized by abnormal lymphocytes and immunoglobulin was observed. The MAN2B2 protein level was not affected, while LC–MS/MS showed obvious disruption of N‐glycans and N‐linked glycoproteins. Conclusion We described a CDG patient with novel phenotypes and disruptive N‐glycan profiling caused by compound heterozygous MAN2B2 variants (c.384G>T; c.926T>A). Our findings broadened both the genetic and clinical spectra of CDG.

Congenital disorders of glycosylation with multiorgan disruption and immune dysregulation caused by compound heterozygous variants in MAN2B2